INVESTOR INFORMATION
From integration to recurring revenue.
ANDYKLA follows a capital-conscious approach: use available humanoid hardware, develop our own AI and companion layer, and validate the business model early in a real CARE environment.
Investment logic
Funding framework
A financing framework of up to €500,000 is currently being evaluated for the initial development and pilot phase. The final amount and capital drawdown are intended to be based on concrete hardware quotations, integration costs and defined milestones.
A strategic equity structure is preferred. Any investment is intended to be structured so that existing IMMUMEDIC activities remain legally and economically separate.
Refinancing
The target model is based on recurring revenue from AI/software usage, service and Robot-as-a-Service. Specific end-customer pricing, margins and break-even timing will be published only after completion of the current manufacturer and cost validation.
No public return promise or fixed equity percentage is being offered. Terms will be agreed individually on the basis of a robust corporate and financing structure.
ANDYKLA is being developed within the IMMUMEDIC Group environment. “IMMUMEDIC Group” currently describes the shared umbrella and network positioning. The legal contracting party and investment entity will be explicitly identified in every transaction.
Request a conversation
Following an initial discussion, qualified investors can receive further information on the roadmap, budget, manufacturer evaluation and potential investment structure.